Evaluation of a hapten conjugate vaccine against the "zombie drug" xylazine.
Chem Commun (Camb)
; 60(35): 4711-4714, 2024 Apr 25.
Article
in En
| MEDLINE
| ID: mdl-38596865
ABSTRACT
Xylazine has emerged as a primary adulterant in fentanyl, exacerbating the complexity of the opioid crisis. Yet, there is no approved drug that can reverse xylazine's pathophysiology. As a prelude to monoclonal antibodies being assessed as a viable therapeutic, a vaccine inquiry was conducted evaluating the immune response in reversing xylazine induced behavior effects.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Xylazine
/
Haptens
Limits:
Animals
Language:
En
Journal:
Chem Commun (Camb)
Journal subject:
QUIMICA
Year:
2024
Document type:
Article
Affiliation country:
Publication country:
ENGLAND
/
ESCOCIA
/
GB
/
GREAT BRITAIN
/
INGLATERRA
/
REINO UNIDO
/
SCOTLAND
/
UK
/
UNITED KINGDOM